Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Nanocarriers Loaded with Oxygen to Improve the Protection of the Heart to be Transplanted

Author(s): Claudia Penna*, Francesco Trotta, Roberta Cavalli and Pasquale Pagliaro*

Volume 28, Issue 6, 2022

Published on: 30 November, 2021

Page: [468 - 470] Pages: 3

DOI: 10.2174/1381612827666211109112723

Abstract

In the case of serious cardiovascular diseases, such as refractory heart failure, heart transplantation is the only possible intervention. Currently, the modes of organ transport in hypothermic cardioplegic solution do not allow the implantation of the heart beyond 4-5 hours from the explant. The heart being an organ with a greater consumption of oxygen and high metabolism than the brain, its transport in hypothermic cardioplegic solutions presents critical issues in terms of time and conservation. An ambitious goal of many researchers and clinicians is to minimize the hypoxia of the explanted heart and extend the permanence time in cardioplegic solution without damage from hypoxia. Adequately oxygenating the explanted organs may extend the usability time of the explanted organ. This challenge has been pursued for years with approaches that are often expensive, risky, and/or difficult to use. We propose to consider oxygenated nanocarriers releasing oxygen for a long time. In this way, it will also be possible to use organs from distant countries with respect to the recipient, thus exceeding the canonical 4-5 hours tolerated up to now. In addition to the lack of oxygen, the transplanted organ can undergo the accumulation of catabolites due to the lack of perfusion during transport. Therefore, nanocarriers can also be perfused in adequate solution during organ transportation. A better oxygenation improving the postoperative recovery of the transplanted heart will improve the recipient's quality of life.

Keywords: α-cyclodextrin, α-cyclodextrin nanosponges, cyclic nigerosyl-nigerose, oxygen, hypoxia, reoxygenation, organ transplantation, nanocarriers.

« Previous Next »
[1]
Regional Transplant Center, Piedmont Region. Available from: 2020www.trapianti.salute.gov.it
[2]
Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 2020; 17(9): 543-58.
[http://dx.doi.org/10.1038/s41569-020-0413-9] [PMID: 32690910]
[3]
Pagliaro P, Thairi C, Alloatti G, Penna C. Angiotensin-converting enzyme 2: a key enzyme in key organs. J Cardiovasc Med (Hagerstown) 2022; 23(1): 1-11.
[http://dx.doi.org/10.2459/JCM.0000000000001218] [PMID: 34091532]
[4]
Lionetti V, Bollini S, Coppini R, et al. Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. Pharmacol Res 2021; 168: 105581.
[http://dx.doi.org/10.1016/j.phrs.2021.105581] [PMID: 33781873]
[5]
Pagliaro P, Aragno M, Penna C. Role of temperature in myocardial ischemic injury and protection by conditioning. Cond Med 2020; 3(1): 31-46.
[6]
Guide to the quality and safety of organs for transplantation. Available from: https://freepub.edqm.eu/publications
[7]
Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2019 Annual Data Report: Heart. Am J Transplant 2021; 21(Suppl. 2): 356-440.
[http://dx.doi.org/10.1111/ajt.16492] [PMID: 33595196]
[8]
Femminò S, Penna C, Bessone F, et al. α-Cyclodextrin and α-cyclodextrin polymers as oxygen nanocarriers to limit hypoxia/reoxygenation injury: Implications from an in vitro model. Polymers (Basel). 2018; 10(2): 211.
[http://dx.doi.org/10.3390/polym10020211]
[9]
Penna C, Femminò S, Caldera F, et al. Cyclic nigerosyl-nigerose as oxygen nanocarrier to protect cellular models from hypoxia/reoxygenation injury: Implications from an in vitro model. Int J Mol Sci. 2021; 22(8):4208.
[http://dx.doi.org/10.3390/ijms22084208]
[10]
Alfì E, Thairi C, Femminò S, et al. Extracellular vesicles (EVs) in ischemic conditioning and angiogenesis: Focus on endothelial derived EVs. Vascul Pharmacol 2021; 140: 106873.
[http://dx.doi.org/10.1016/j.vph.2021.106873] [PMID: 33992781]
[11]
Chew HC. The donor heart and organ perfusion technology. J Thoracic Dis 2019; 11(Suppl 6): S938-45.
[http://dx.doi.org/10.21037/jtd.2019.02.59]
[12]
Terraneo L. Hemoglobin extravasation in the brain of rats exchange-transfused with hemoglobin-based oxygen carriers. Artificial cells, nanomedicine, and biotechnology 2017; 45(4): 710-6.
[http://dx.doi.org/10.1080/21691401.2016.1263640]
[13]
Pagliaro P. Differential biological effects of products of nitric oxide (NO) synthase: it is not enough to say NO. Life Sci 2003; 73(17): 2137-49.
[http://dx.doi.org/10.1016/S0024-3205(03)00593-9] [PMID: 12927585]
[14]
Yu B. Hemoglobin-based red blood cell substitutes and nitric oxide. Trends Cardiovasc Med 2009; 28(9): 784-94.
[http://dx.doi.org/10.1016/j.tcm.2009.06.004]
[15]
Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, Vavia P. Nanosponge formulations as oxygen delivery systems. Int J Pharm. 2010; 402(1-2): 254-257.
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.025]
[16]
Haider N, Fatima S, Taha M, et al. Nanomedicines in diagnosis and treatment of cancer: An update. Curr Pharm Des 2020; 26(11): 1216-31.
[http://dx.doi.org/10.2174/1381612826666200318170716] [PMID: 32188379]
[17]
Ansari MA, Chung I-M, Rajakumar G, et al. Current nanoparticle approaches in nose to brain drug delivery and anticancer therapy - a review. Curr Pharm Des 2020; 26(11): 1128-37.
[http://dx.doi.org/10.2174/1381612826666200116153912] [PMID: 31951165]
[18]
Fu H, Fu J, Ma S, Wang H, Lv S, Hao Y. An ultrasound activated oxygen generation nanosystem specifically alleviates myocardial hypoxemia and promotes cell survival following acute myocardial infarction. J Mater Chem B Mater Biol Med 2020; 8(28): 6059-68.
[http://dx.doi.org/10.1039/D0TB00859A] [PMID: 32697256]
[19]
Zhang Y, Wan Y, Chen Y. Ultrasound-enhanced chemo-photodynamic combination therapy by using albumin “Nanoglue”-based nanotheranostics. ACS Nano 2020; 14(5): 5560-9.
[http://dx.doi.org/10.1021/acsnano.9b09827]
[20]
Kankala RK, Zhu K, Sun XN, Liu CG, Wang SB. Cardiac tissue engineering on the nanoscale. ACS Biomaterials Science & Engineering 2018; 4(3): 800-18.
[http://dx.doi.org/10.1021/acsbiomaterials.7b00913]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy